Hospital bed size and sepsis-related complications in patients with Myelodysplastic Syndromes: Insights from the national inpatient sample (2016–2022)

J Jatin Thukral (Landmark Medical Center, Woonsocket, Cumberland, Rhode Island, United States) S Sooraj Srirangadhamu Gopu (1New York Medical College/Landmark Medical Center, Hematology-Oncology, Woonsocket, United States) S Salman Ayub Jajja (NYMC-LANDMARK MEDICAL CENTER, RI, Woonsocket, Rhode Island, United States) D Dhruvi Joshi (Narendra Modi Medical College and Sheth L.G. Hospital, Ahmedabad, India) H Harbir Kaur (6Hamilton Medical Center, Internal Medicine, Dalton, United States) V Vida Tajiknia (1New York Medical College/Landmark Medical Center, Hematology-Oncology, Woonsocket, United States) K Kanishka Uttam Chandani (4Mayo Clinic, Hematology-Oncology, Phoenix, United States) A Amanda Lussier (1New York Medical College/Landmark Medical Center, Hematology-Oncology, Woonsocket, United States) N Nikhil Thukral (Pt. Deendayal Upadhyaya National Institute For Persons with Physical Disabilities, Oakland, California, United States) O Omar Alkasabrah (Landmark Medical center, Providence, Rhode Island, United States) A Ahmed Nadeem (1New York Medical College/Landmark Medical Center, Hematology-Oncology, Woonsocket, United States)

Abstract

Abstract Background: Patients with myelodysplastic syndromes (MDS) are at heightened risk for severe infections, including sepsis, due to underlying cytopenias and immune dysregulation. Hospital-level characteristics, including size and available resources, may influence clinical outcomes in these patients, but data remain limited. This study examines the association between hospital bed size and sepsis-related complications in patients with MDS using a nationally representative dataset. Methods: We conducted a retrospective cohort analysis using the National Inpatient Sample (NIS) from 2016 to 2022, identifying adult hospitalizations with co-diagnoses of MDS and sepsis. Hospitalizations were stratified by hospital bed size: small (n = 15,490), medium (n = 22,815), and large (n = 40,245). Multivariable logistic regression, adjusted for patient demographics, comorbidities, and hospital characteristics, was used to assess associations between hospital bed size and eight clinical outcomes: in-hospital mortality, septic shock, acute renal failure, respiratory failure, encephalopathy, disseminated intravascular coagulation (DIC), Clostridioides difficile infection (CDI), and fungal sepsis. Results: Compared to small hospitals, patients treated at large hospitals had significantly higher odds of in-hospital mortality (OR 1.43, p < 0.001), septic shock (OR 1.25, p < 0.001), acute renal failure (OR 1.10, p < 0.001), encephalopathy (OR 1.11, p = 0.004), DIC (OR 1.48, p = 0.007), and fungal sepsis (OR 2.13, p = 0.028). Medium-sized hospitals were also associated with increased odds of mortality (OR 1.16, p = 0.021) and septic shock (OR 1.13, p = 0.038). No statistically significant differences were found in rates of CDI across hospital sizes. Respiratory failure showed a borderline association in medium hospitals (OR 1.05, p = 0.082) but not in large hospitals. Conclusion: Hospital bed size is independently associated with important variations in sepsis-related outcomes among patients with MDS. Large hospitals demonstrated significantly increased odds of multiple complications and mortality, possibly reflecting referral bias, higher disease acuity, or institutional coding practices. These findings underscore the importance of hospital-level factors in evaluating outcomes and resource planning for high-risk hematologic populations. Keywords: Myelodysplastic syndromes, hospital bed size, sepsis, mortality, ICU complications, NIS

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue Supplement 1
Published November 03, 2025
Pages 8197-8197
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (11)

J

Jatin Thukral

Landmark Medical Center, Woonsocket, Cumberland, Rhode Island, United States

S

Sooraj Srirangadhamu Gopu

1New York Medical College/Landmark Medical Center, Hematology-Oncology, Woonsocket, United States

S

Salman Ayub Jajja

NYMC-LANDMARK MEDICAL CENTER, RI, Woonsocket, Rhode Island, United States

D

Dhruvi Joshi

Narendra Modi Medical College and Sheth L.G. Hospital, Ahmedabad, India

H

Harbir Kaur

6Hamilton Medical Center, Internal Medicine, Dalton, United States

V

Vida Tajiknia

1New York Medical College/Landmark Medical Center, Hematology-Oncology, Woonsocket, United States

K

Kanishka Uttam Chandani

4Mayo Clinic, Hematology-Oncology, Phoenix, United States

A

Amanda Lussier

1New York Medical College/Landmark Medical Center, Hematology-Oncology, Woonsocket, United States

N

Nikhil Thukral

Pt. Deendayal Upadhyaya National Institute For Persons with Physical Disabilities, Oakland, California, United States

O

Omar Alkasabrah

Landmark Medical center, Providence, Rhode Island, United States

A

Ahmed Nadeem

1New York Medical College/Landmark Medical Center, Hematology-Oncology, Woonsocket, United States